Skip to Main Content

INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102

Conditions

Non-Hodgkin's Lymphoma | Phase I

Phase I

What is the purpose of this trial?

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC. Both intermediate risk and BCG-unresponsive NMIBC participants will be included.

  • Trial with
    Eisai Pharmaceuticals
  • Start Date
    07/30/2020
  • End Date
    10/31/2022

For more information about this study, contact:

Ingrid Palma

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/13/2020
  • Study HIC
    #2000026758